Crossmark

Multi-omics analysis identified LGALS1 (Galectin-1) as a novel therapeutic target for clear cell renal cell carcinoma via targeting epithelial or endothelial cells

Crossref DOI link: https://doi.org/10.1007/s12672-025-03750-2

Published Online: 2025-10-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tan, Xiangyin

Chen, Yingfei

Jiang, Chao

Shao, Jialiang

Wang, Xiang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82372747)
License Information

Text and Data Mining valid from 2025-10-15

Version of Record valid from 2025-10-15
More Information

Article History

Received: 27 May 2025

Accepted: 25 September 2025

First Online: 15 October 2025

Declarations

:

: The IHC chip development of this work was approved by the ethics committee of the SHANGHAI OUTDO BIOTECH CO. LTD (protocol code: SHYJS-CP-240303).

: Written informed consent was obtained from the patient for publication of the clinical messages and any accompanying images.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below